Nicousamide blocks the effects of advanced glycation end products on renal cells

被引：11
作者：
Li, Hongyan [1 ,2 ,3 ]
Zhang, Yi [1 ,2 ]
Wang, Hongbo [1 ,2 ]
Zheng, Xuguang [1 ,2 ]
Chen, Xiaoguang [1 ,2 ]
机构：
[1] Chinese Acad Med Sci, Dept Pharmacol, Inst Mat Med, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100050, Peoples R China
[3] NIDDK, NIH, Bethesda, MD USA
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2012年 / 674卷 / 2-3期
基金：
中国国家自然科学基金;
关键词：
Nicousamide; AGE (Advanced glycation end products); TGF-beta 1 (Transforming growth factor-beta 1); CTGF (Connective tissue growth factor); MMPs (Matrix metalloproteinase); TISSUE GROWTH-FACTOR; RAT MESANGIAL CELLS; DIABETIC-NEPHROPATHY; EXTRACELLULAR-MATRIX; MAILLARD REACTION; FACTOR-BETA; IN-VITRO; COMPLICATIONS; PROGRESSION; EXPRESSION;
D O I：
10.1016/j.ejphar.2011.06.056
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advanced glycation end products (AGE) are key factors in the pathogenesis of diabetic nephropathy. AGE can stimulate the expressions of fibrogenic transforming growth factor (TGF-beta 1) and connective tissue growth factor (CTGF), which in turn induce renal hypertrophy, sclerosis and functional failure. The purpose of this study was to examine nicousamide, a novel coumarin aspirin derivative, in the treatment of diabetic nephropathy using a renal mesangial and tubular epithelia cell model. RT-PCR and ELISA analyses showed that nicousamide inhibited AGE-induced TGF-beta 1 and CTGF. Nicousamide blocked AGE-induced G1-arrest in mesangial cells and tubular epithelia by flow cytometry. Suppression of matrix metalloproteinase activity by AGE was restored by nicousamide. This study supports that nicousamide retards diabetic nephropathy by blocking the effects of AGE on renal cells. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：455 / 459
页数：5
相关论文
共 44 条
[1]   Advanced glycation endproducts: what is their relevance to diabetic complications? [J].
Ahmed, N. ;
Thornalley, P. J. .
DIABETES OBESITY & METABOLISM, 2007, 9 (03) :233-245
[2]  
Ban CR, 2008, VASC HEALTH RISK MAN, V4, P575
[3]   Prevention of loss of renal function over time in patients with diabetic nephropathy [J].
Barnett, A .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (05) :40S-47S
[4]   Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells [J].
Berrou, J. ;
Tostivint, I. ;
Verrecchia, F. ;
Berthier, C. ;
Boulanger, E. ;
Mauviel, A. ;
Marti, H. P. ;
Wautier, M. P. ;
Wautier, J. L. ;
Rondeau, E. ;
Hertig, A. .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 23 (04) :513-520
[5]   Advanced glycation end products and the kidney [J].
Bohlender, JM ;
Franke, S ;
Stein, G ;
Wolf, G .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (04) :F645-F659
[6]   CTGF expression in mesangial cells: Involvement of SMADs, MAP kinase, and PKC [J].
Chen, YJ ;
Blom, IE ;
Sa, S ;
Goldschmeding, R ;
Abraham, DJ ;
Leask, A .
KIDNEY INTERNATIONAL, 2002, 62 (04) :1149-1159
[7]   Diabetic nephropathy: Where hemodynamics meets metabolism [J].
Forbes, J. M. ;
Fukami, K. ;
Cooper, M. E. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 (02) :69-84
[8]   Role of advanced glycation end products in diabetic nephropathy [J].
Forbes, JM ;
Cooper, ME ;
Oldfield, MD ;
Thomas, MC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 :S254-S258
[9]   Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes -: Effects of ACE inhibition [J].
Gilbert, RE ;
Cox, A ;
Wu, LL ;
Allen, TJ ;
Hulthen, UL ;
Jerums, G ;
Cooper, ME .
DIABETES, 1998, 47 (03) :414-422
[10]   The role of advanced glycation end products in progression and complications of diabetes [J].
Goh, Su-Yen ;
Cooper, Mark E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) :1143-1152
12345